**Author details**

Abdulla Arslan\* and Hakan Altay Department of Cardiology, Faculty of Medicine, Baskent University, Istanbul, Turkey

\*Address all correspondence to: apaslan@msn.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Graves' Disease and Cardiac Complications DOI: http://dx.doi.org/10.5772/intechopen.97128*

### **References**

[1] Anthony P. Weetman , MD, D.SC GRAVES' DISEASE Review Article, The New England Journal of Medicine

[2] Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998;19:673-716. [Erratum, Endocr Rev 1999;20:100.]

[3] Bulow PI, Laurberg P, Knudsen N, et al. Increase in incidence of hyprthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark. J Clin Endocrinol Metab 2006; 91: 3830-3834

[4] Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-243.

[5] Vanderpump MPJ, Tunbridge WMG. The epidemiology of autoimmune thyroid disease. In: Volpe R, ed. Autoimmune endocrinopathies. Vol. 15 of Contemporary endocrinology. Totowa, N.J.: Humana Press,1999:141-62.

[6] Takata I, Suzuki Y, Saida K, Sato T. Human thyroid stimulating activity and clinical state in antithyroid treatment of juvenile Graves' disease. Acta Endocrinol (Copenh) 1980;94:46-52.

[7] Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.

[8] Ghandour A, Reust C. Hyperthyroidism: a stepwise approach to treatment. J Fam Pract 2011; 60: 388-395

[9] Palitzsch KD. Prevention and multimodal therapy of hyperthyroidism. Internist (Berl) 2008; 49: 1428-1436

[10] Brandt F, Green A, Hegedüs L, Brix TH. A critical review and metaanalysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011; 165:491-497.

[11] Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995;273:808-812.

[12] Brent G. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331:847-853

[13] Everts ME, Verhoeven FA, Bezstarosti K, Moerings EP, Hennemann G, Visser TJ, Lamers JM. Uptake of thyroid hormones in neonatal ratcardiac myocytes. Endocrinology. 1996;137:4235-4242

[14] Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocrine Rev. 2005;26:704-728.

[15] Leng X, Bianco J, Tsai SY, Ozato K, O'Malley BW, Tsai MJ. Mechanisms for synergic activation of thyroid hormone receptor and retinoid X receptor on different response elements. J Biol Chem 1994; 269: 31436-31442

[16] Ribeiro RC, Apriletti JW, West BL, et al. The molecular biology of thyroid hormone action. Annual N Y Acad Sci 1995; 758: 266-289

[17] Lazar MA, Chin WW. Nuclear thyroid hormone receptors. J Clin Invest.1990;86:1777-1782

[18] Ojamaa K, Klemperer JD, MacGlivray SS. Thyroid hormone and hemodynamic regulation of betamyosin heavy chain promoter in the heart. Endocrinology 1996; 137: 802-808

[19] Wu Y, Koenig RJ. Gene regulation by thyroid hormone. Trends EndocrinolMetab. 2000;11:207-211.

[20] Hu X, Lazar MA. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab. 2000;11:6-10

[21] Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab. 1991;73:146-150

[22] Hiroi Y, Kim H-H, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen N-H, Scanlan TS, Moskowitz MA, Cheng S-Y, Liao JK. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A. 2006;103:14104-14109

[23] Dillman WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88: 626-630

[24] Kiss E, Jakab G, Kranias EG, et al. Thyroid hormoneinduced alteration in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res 1994; 75:245-251

[25] Tsika RW, Bahl JJ, Leinwand LA, Morkin E. Thyroid hormone regulates expression of a transfected human alphamyosin heavy chain fusion gene in fetal rat heart cells. Proc Natl Acad Sci USA 1990; 87: 379-383.

[26] Averyheart-Fullard V, Fraker LD, Murphy AM, Solaro RJ. Differential regulation of slow skeletal and cardiac troponon I mRNA during development and by thyroid hormone in rat heart. J Mol Cell Cardiol 1994; 26: 609-616

[27] Morkin E. Regulation of myosin heavy chain genes in the heart. Circulation 1993; 87: 1451-1460.

[28] Izumo S, Nadal-Ginard B, Mahdavi V. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific manner. Science 1986; 231:597-600

[29] Ladenson PW, Sherman SI, Boughman RL. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 1992; 89: 5251-5255

[30] Magner J, Clarck W, Allenby P. Congestive heart failure and sudden death in a young woman with thyrotoxicosis. West J Med 1988; 110: 759-760

[31] Kiss E, Brittsan AG, Elds I, et al. Thyroid hormone-induced alterations in phospholamban deficient mouse hearts. Circ Res 1998; 83: 608-13

[32] Panagoulis C, Halapas A, Chariatis E, Driva P, Matsakas E. Hyperthyroidism and heart. Hellenic J Cardiol 2008; 49:169-175

[33] Kasturi S, Ismail-Beigi F. Effect of thyroid hormone on the distribution and activity of Na, K ATPase in ventricular myocardium. Arch Biochem Biophys 2008; 475: 121-127

[34] Ojamaa K, Sabet A, Kenessey A, et al. Regulation of rat cardiac Kv 1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 1999; 140: 3170-3176.

[35] Chen WJ, Yeh YH, Lin KH, Chang GJ, Kuo CT. Molecular characterisation of thyroid hormoneinhibited atrial Ltype calcium channel expression: implication for atrial fibrillation in hyperthyroidism. Basic res Cardiol 2011; 106:163-174

[36] Hammond HK, White FC, Buxton IL, Salzstein P, Brunton LL, Longhurst JC. Increased myocardial beta-recepors and adrenergic responses in hyperthyroid pigs. Am J Physiol 1987; 252: H283–H290

*Graves' Disease and Cardiac Complications DOI: http://dx.doi.org/10.5772/intechopen.97128*

[37] Levey GS, Klein I. Cathecholamine thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med 1990; 88: 642-646

[38] Ojamaa K, Klein I, Sabet A, Steinberg SF. Chnages in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta adrenergic receptor responsiveness. Metabolism 2000; 49: 275-279

[39] Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998; 27: 51-62

[40] Davis PJ, Davis FB. Acute cellular actions of thyroid hormone and myocardial function. Ann Thorac Surg 1993; 56 (Suppl.): S16-23

[41] Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary artery by-pass surgery. N Eng J Med 1995; 333: 1522-1527

[42] Walker JD, Crawford FA, Kato S, et al. The novel effects of 3,5,3′-triiodo-L-thyronine on myocyte contractile function and beta adrenergic responsiveness in dilated cardiomyopathy. J Thorac Cardiovasc Surg 1994; 108: 672

[43] Cacciatori V, Bellavere F, Pessarosa A, et al. Power spectral analysis of heart rate in hyperthyroidism. J Clin End Metab 1996; 81: 2828

[44] Ojamaa K, Kenessey A, Klein I. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology 2000; 141: 2139-2144

[45] Messarah M, Saoudi M, Boulakaud MS, Feki AE. Oxidative stress induced by thyroid dysfunction in rat erythrocytes and heart. Environ Toxicol Pharmacol 2011; 31: 33-41

[46] Resnick LM, Laragh JH. Plasma rennin activity in syndromes of hyroid hormone excess and deficiency. Life Sci 1982; 30: 585-586

[47] Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996; 6:505

[48] Vargas-Uricoechea H, Bonelo-Perdomo A, Sierra-Torres CH. Effects of thyroid hormones on the heart. Clin Investig Arterioscler. 2014 Nov-Dec;26(6):296-309

[49] Nabbout LA, Robbins RJ. The cardiovascular effects of hyperthyroidism.Methodist DeBakey Cardiovasc J. 2010 Apr-Jun;6(2):3-8

[50] Imai T, Hirata Y, Iwashina M, Marumo F. Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology. 1995;136:1544-1548

[51] Diekman MJ, Harms MP, Endert E, Wieling W, Wiersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol. 2001;144:339-346

[52] Nordyke RA, Gilbert FI Jr, Harada ASM. Graves' disease: influence of age on clinical findings. Arch Intern Med 1988;148:626-631

[53] Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Minerva Endocrinologica. 2004;29:139-150

[54] Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeleteal muscle resistance arteries. Anesth Analog 1997; 85: 734-738

[55] Klein I, Levey GS. Unusual manifestations of hypo thy roidism. Arch Intern Med 1984; 144: 123-128

[56] Fadel BM, Ellahham S, Ringel MD, Lindsay J, Wartofsky L, Burman KD. Hyperthyroid heart disease. Clin Cardiol 2000; 23: 402-408

[57] Theilen EO, Wilson WR. Hemodynamic effects of peri pheral vasoconstriction in normal and thyrotoxic subjects.J Appl Physiol 1967; 22: 207-210

[58] Asvold BO, Bjoro T, Nilsen T, Vatten LJ. Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J Clin Endocrinol Metab. 2007;9:841-845

[59] Volzke H, Alte D, Dorr M, Wallaschofski H, John U, Felix SB, Rettig R. The association between subclinical hyperthyroidism and blood pressure in a population-based study. J Hypertens. 2006;24:1947-1953

[60] Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Cur Hypertens Rep. 2003;5:513-520

[61] Palmieri EA, Fazio S, Palmieri V, Lombardi G, Biondi B. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol.2004;150:757-762

[62] Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens. 2006;8:596-599

[63] Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, Fazio S, Sacca L. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001;104:3076-3080

[64] Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Chiadoni L, Salvetti A, Ferrannini E, Monzani F. Impaired endothelium-dependent

vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88:3731-3737

[65] Guntekin U, Gunes Y, Tuncer M, et al. QTc dispersion in hyperthyroidism and its association with pulmonary hypertension. Pacing Clin Electrophysiol 2009; 32: 494-499

[66] Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res 2009; 2: 4

[67] Wustmann K, Kucera JP, Zanchi A, et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab 2008; 93:2104

[68] Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142: 838

[69] Vardas PE, Mavrakis HE. Atrial fibrillation: a symptom treated as a disease? Hellenic J Cardiol 2006; 47: 191-193

[70] Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, Hardman SM. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21:327-333

[71] Krahn AD, Klein GJ, Kerr CR, Boone J, Sheldon R, Green M, Talajic M, Wang X, Connolly S. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med. 1996;156:2221-2224

[72] Almeida NA, Corderio A, Machado DS, et al. Connexin 40 messenger ribonucleic activity is posotovely regulated by thyroid hormone (TH)acting in cardiac atria via *Graves' Disease and Cardiac Complications DOI: http://dx.doi.org/10.5772/intechopen.97128*

the THreceptor. Endocrinology 2009; 150: 546-554

[73] Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-906

[74] Kim D, Smith TW. Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. *J Clin Invest*. 1984;74:1481-1488. 87

[75] Roti E, Montermini M, Roti S, Gardini E, Robuschi G, Minelli R, Salvi M, Bentivoglio M, Guiducci U, Braverman LE. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med. 1988;148:1919-1192

[76] Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12:489-493.

[77] Chaudhury S, Ismail-Beigi F, Gick GG, Levenson E, Edel man IS. Effect of thyroid hormone on the abundance of Na,K,ATPase alpha subunit messenger ribonucleic acid.Mol Endocrinol 1987; 1: 83-89

[78] Lin H, Mitasikova M, Dlugosova K, et al. Thyroid hormones suppress epsilon PKC-signalling, downregulate connexin- 43 and increase lethal arrhythmia susceptibility in nondiabetic and diabetic rats. J Phsiol Pharm 2008; 59: 271-285

[79] Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular symptoms and cardiac rate and rhythm abnormalities improve with treatment in patients with hyperthyroidism. J Am Coll Cardiol. 2007;49:71-81

[80] Danzi S, Klein I. Thyroid disease and the cardiovascular system. Endocrinol Metab Clin North Am. 2014 Jun;43(2):517-528

[81] Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol. 2016 Feb;41(2):65-92

[82] Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol. 2012 Nov;167(5):609-618

[83] Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease.Thyroid 2002; 12: 473

[84] Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Re 2008; 5: 170-176.

[85] Yue WS, Chong BH, Zhang XH, et al. Hyperthyroidisminduced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure. Clin Endocrinol (Oxf) 2011; 74: 636-643

[86] Klein I. Endocrine disorders and cardiovascular disease. In: Zipes DP,Libby P, Bonow R, Braunwald E, eds. *Braunwald's Heart Disease: ATextbook of Cardiovascular Medicine*. 7th ed. Philadelphia, Pa. W.B.Saunders; 2005:2051-2065.

[87] Evangelopoulou ME, Alevizaki M, Toumanidis S, Piperingos G, Mavrikakis M, Sotou D, Evangelopoulou K, Koutras DA. Mitral valve prolapse in autoimmune thyroid disease: an index of systemic autoimmunity? Thyroid. 1999;9:973-977

[88] Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a populationbased study. Arch Intern Med. 2004; 164:1675-1678

[89] Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252

[90] Merce J, Ferras S, Oltra C, Sanz E, Vendrell J, Simon I, Camprubi M, Bardaji A, Ridao C. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med. 2005;118:126-133

[91] Paran Y, Nimrod A, Goldin Y, Justo D. Pulmonary hypertension and predominant right heart failure in thyrotoxicosis. Resuscitation. 2006; 69:339-341.

[92] Ventrella S, Klein I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. The Endocrinologist. 1994;4:391-399

[93] Delit C, Silver S, Yohalem SB, Segal RL. Thyrocardiac disease and its management with radioactive iodine I-131. JAMA. 1961;29:262-267

[94] Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294:71-80

[95] Tsymbaliuk I, Unukovych D, Shvets N, Dinets A (2015) Cardiovascular Complications Secondary to Graves' Disease: A Prospective Study from Ukraine. PLoS ONE 10(3): e0122388. doi:10.1371/ journal.pone.0122388

[96] Scerrino G, Morfino G, Paladino NC, Di Paola V, Amodio E, Gulotta G, et al. Does thyroid surgery for Graves' disease improve health-related quality of life? Surgery today. 2013; 43(12):1398-405. Epub 2012/12/12. doi: 10.1007/s00595-012- 0442-z PMID: 23229839

[97] Jiang SY, Xu M, Ma XW, Xiao H, Zhang YY. A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin Exp Pharmacol Physiol. 2010; 37(9):919-25. doi: 10.1111/j.1440- 1681.2010.05404.x PMID: 20497424

[98] Vallabhajosula S, Radhi S, Cevik C, Alalawi R, Raj R, Nugent K. Hyperthyroidism and pulmonary hypertension: an important association. Am J Med Sci. 2011 Dec;342(6):507-512

[99] Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab. 2007 May;92(5):1736-1742

[100] Sugiura T, Yamanaka S, Takeuchi H, Morimoto N, Kamioka M, Matsumura Y. Autoimmunity and pulmonary hypertension in patients with Graves' disease. Heart Vessels. 2015 Sep;30(5):642-646

[101] Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med. 2006;17:267-271

[102] Ma RC, Cheng AY, So WY, Hui DS. Thyrotoxicosis and pulmonary hypertension. Am J Med. 2005;118:927-928

[103] Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci. 1999;318:289-292

[104] Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:287-293

*Graves' Disease and Cardiac Complications DOI: http://dx.doi.org/10.5772/intechopen.97128*

[105] Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomised, crossover trial. J Clin Endocrinol Metab. 2007;92:1715-1723

[106] Rush J, Danzi S, Klein I. Role of thyroid disease in the development of statin-induced myopathy. The Endocrinologist. 2006;16:279-285

[107] Drover VAB, Agellon LB. Regulation of the human cholesterol 7α-hydroxylase gene (*CYP7A1*) by thyroid hormone in transgenic mice. Endocrinology. 2004;145:574-581

[108] Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-278

[109] Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002 Dec 3;137(11):904-914.

[110] Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015 Sep;4(3):149-163

[111] Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 2012 Mar;97(3):852-861

[112] Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012 Nov 27;345: e7895

[113] Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014 Jul;99(7):2372-2382

[114] Gu LQ, Zhao L, Zhu W, et al. Relationships between serum levels of thyroid hormones and serum concentrations of symmetric dimethylarginine (ADMA) and N-terminal-pro B-type natriuretic peptide (NT-proBNP) in patients with Graves' disease. Endocrine 2011; 39: 266-271

[115] Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343}}

[116] Subahi A, Ibrahim W, Abugroun A. Diltiazem-Associated Cardiogenic Shock in Thyrotoxic Crisis. Am J Ther 2018; 25:e666.

[117] Klein I, Biondi B. Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Bonow RO, Mann DL, Tomaselli GF, Bhatt D (Eds), Saunders Elsevier, Philadelphia 2019. p.1807.

Section 4
